Compare PLTK & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLTK | DFTX |
|---|---|---|
| Founded | 2010 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2020 | N/A |
| Metric | PLTK | DFTX |
|---|---|---|
| Price | $2.74 | $17.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $5.25 | ★ $40.25 |
| AVG Volume (30 Days) | ★ 2.0M | 1.3M |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 14.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,755,400,000.00 | N/A |
| Revenue This Year | $3.07 | N/A |
| Revenue Next Year | $2.43 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.08 | N/A |
| 52 Week Low | $2.68 | $14.62 |
| 52 Week High | $5.59 | $18.70 |
| Indicator | PLTK | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.14 | 51.34 |
| Support Level | N/A | $16.31 |
| Resistance Level | $3.87 | $18.10 |
| Average True Range (ATR) | 0.20 | 0.96 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 7.51 | 66.52 |
Playtika Holding Corp is engaged in developing mobile games. Some of its games include Board Kings, House of Fun, Poker Heat, Slotomania, and Bingo Blitz. The company has built live game operations services and a proprietary technology platform to support its portfolio of games. It derives revenue from the sale of virtual items associated with online games. Geographically, the group has a business presence in the USA, EMEA, APAC, and Other regions of which key revenue is derived from the USA. It offers both Mobile and Web-based platforms.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).